EHS
EHS

Editorial: Intranasal Delivery of Central Nervous System Active Drugs: Opportunities and Challenges


Editorial


doi: 10.3389/fphar.2022.927812.


eCollection 2022.

Affiliations

Item in Clipboard

Editorial

Márcio Rodrigues et al.


Front Pharmacol.


.

No abstract available


Keywords:

brain targeting; central nervous system; intranasal drug delivery; nasal route; pharmacodynamics; pharmacokinetics.

Conflict of interest statement

The authors declare that the research was conducted in the absence of any commercial or financial relationships that could be construed as a potential conflict of interest.

Comment on

  • Editorial on the Research Topic Intranasal Delivery of Central Nervous System Active Drugs: Opportunities and Challenges

References

    1. Agarwal S. K., Kriel R. L., Brundage R. C., Ivaturi V. D., Cloyd J. C. (2013). A Pilot Study Assessing the Bioavailability and Pharmacokinetics of Diazepam after Intranasal and Intravenous Administration in Healthy Volunteers. Epilepsy Res. 105, 362–367. 10.1016/j.eplepsyres.2013.02.018



      DOI



      PubMed

    1. Cartt S., Medeiros D., Gwozdz G. T. (2012). Patent US9763876B2. (United States: Applicant: Hale Biopharma Ventures LLC; ). Available at: https://patents.google.com/patent/US9763876B2/en .

    1. Erdő F., Bors L. A., Farkas D., Bajza Á., Gizurarson S. (2018). Evaluation of Intranasal Delivery Route of Drug Administration for Brain Targeting. Brain Res. Bull. 143, 155–170. 10.1016/j.brainresbull.2018.10.009



      DOI



      PubMed

    1. Fortuna A., Alves G., Serralheiro A., Sousa J., Falcão A. (2014). Intranasal Delivery of Systemic-Acting Drugs: Small-Molecules and Biomacromolecules. Eur. J. Pharm. Biopharm. 88, 8–27. 10.1016/j.ejpb.2014.03.004



      DOI



      PubMed

    1. Hogan R. E., Tarquinio D., Sperling M. R., Klein P., Miller I., Segal E. B., et al. (2020). Pharmacokinetics and Safety of VALTOCO (NRL-1; Diazepam Nasal Spray) in Patients with Epilepsy during Seizure (Ictal/peri-ictal) and Nonseizure (Interictal) Conditions: A Phase 1, Open-Label Study. Epilepsia 61, 935–943. 10.1111/epi.16506



      DOI



      PMC



      PubMed



Source link

EHS
Back to top button